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BACKGROUND: To compare detection rates and evaluate the clinical relevance of cytokeratin-19 (CK-19) mRNA-positive cells in the
peripheral blood (circulating tumour cells, CTCs) and bone marrow (disseminated tumour cells; DTCs) of patients with early breast
cancer.
METHODS: Paired samples of peripheral blood and bone marrow were obtained from 165 patients with stage I–II breast cancer before
the initiation of adjuvant chemotherapy. In 84 patients, paired blood and bone marrow samples were also available after
chemotherapy. The detection of CK-19 mRNA-positive CTCs and DTCs was assessed by real-time PCR.
RESULTS: CK-19 mRNA-positive CTCs and DTCs were detected in 55.2 and 57.6% of patients before chemotherapy, respectively.
After chemotherapy, CTCs and DTCs were identified in 44 (52.4%) and 43 (51.2%) of the 84 patients, respectively. There was a
93.9% (McNemar; P¼0.344) and 72.6% (McNemar; P¼0.999) concordance between blood and bone marrow samples before and
after chemotherapy, respectively. The detection of CK-19 mRNA-positive CTCs or DTCs before chemotherapy was associated with
decreased overall survival (P¼0.024 and P¼0.015, respectively). In addition, their simultaneous detection was also associated with
an increased incidence of disease-related death and decreased overall survival (P¼0.016).
CONCLUSIONS: The detection of CK-19 mRNA-positive CTCs using reverse transcription-PCR (RT–PCR) both before and after
chemotherapy is correlated with the detection of CK-19 mRNA-positive DTCs in patients with early-stage breast cancer. The
determination of the CTC status by RT–PCR conveys clinically relevant information that is not inferior to DTC status and, owing to
the ease of sampling, warrants further evaluation as a tool for monitoring minimal residual disease.
British Journal of Cancer (2009) 101, 589–597. doi:10.1038/sj.bjc.6605183 www.bjcancer.com
Published online 21 July 2009
& 2009 Cancer Research UK
Keywords: breast cancer; circulating tumour cells; CK-19; micrometastasis; disseminated tumour cells
                                                         
Although adjuvant chemotherapy and hormone treatment have
improved disease-free and overall survival (OS) (EBCTC Group,
2005), almost 30% of patients with node-negative breast cancer will
present distant metastases and will die as a result of disseminated
disease (EBCTC Group, 1998). This is due to early tumour-cell
dissemination through the lymphatic or the hematogenous
vasculature (Dowlatshahi et al, 1997; Giatromanolaki et al, 2004;
Stathopoulos et al, 2005). Indeed, epithelial tumour cells can be
identified in bone marrow aspirates (disseminated tumour cells,
DTCs) or in the peripheral blood (circulating tumour cells, CTCs)
of otherwise metastases-free breast cancer patients using either
immunohistochemical or molecular assays (Schoenfeld et al, 1997;
Pantel et al, 1999; Slade et al, 1999).
The immunocytochemical detection of DTCs has been shown to
be associated with decreased disease-free survival (DFS) and OS of
patients with operable breast cancer (Mansi et al, 1999; Braun et al,
2000b; Wiedswang et al, 2003; Braun and Naume, 2005). We have
reported earlier that the detection of CTCs before the initiation of
adjuvant chemotherapy in patients with operable breast cancer,
irrespective of the presence of axillary lymph node involvement
(Stathopoulou et al, 2002; Wiedswang et al, 2003; Xenidis et al,
2006), or an oestrogen/progesterone or HER2 receptor expression
(Ignatiadis et al, 2007), is also an independent factor associated
with decreased DFS and OS.
The detection of DTCs and CTCs during both adjuvant and
metastatic settings could be a useful tool for monitoring the
efficacy of systemic treatment. It has been reported that adjuvant
chemotherapy may eliminate DTCs (Braun et al, 2000a) or CTCs
(Xenidis et al, 2003) in only 50% of patients. Moreover, the
detection of CTCs during the administration of adjuvant tamoxifen
is associated with decreased DFS and OS (Xenidis et al, 2007).
Finally, Cristofanilli et al (2004) showed that the decrease in the
absolute number of CTCs during chemotherapy in patients with
metastatic breast cancer could be considered as an early event,
indicating the efficacy of treatment. However, in patients with
early breast cancer, who are asymptomatic, repeated and frequent
bone marrow aspirations for the detection of DTCs may not be
easily acceptable. Conversely, the use of blood for detecting CTCs
is more convenient and could be easily acceptable by patients, thus
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srepresenting a valuable alternative solution. Although some
previous studies (Ismail et al, 2004; Pierga et al, 2004; Muller
et al, 2005; Benoy et al, 2006; Wiedswang et al, 2006) have shown a
correlation between the detection of DTCs and CTCs, this fact has
not been unanimously accepted. This could be due to the fact that
in most studies, the comparison of the detection of CTCs and
DTCs was carried out using immunocytochemical assays, which, in
general, have a lower sensitivity compared with molecular assays.
The main objective of this study was the direct comparison of
the detection rate of cytokeratin-19 (CK-19) mRNA-positive CTCs
and DTCs in paired samples of the peripheral blood and bone
marrow obtained from patients with early breast cancer. The
secondary objective was the evaluation of their prognostic
significance in the same group of patients hypothesising that
peripheral blood sampling could replace bone marrow aspiration
as a prognostic tool in patients with early breast cancer.
PATIENTS AND METHODS
Patients
A study evaluating the clinical relevance of CK-19 mRNA-positive
CTCs and/or DTCs in patients with early stage or metastatic breast
cancer has been underway since 1996 at the Department of Medical
Oncology at the University Hospital of Heraklion (Crete, Greece).
Peripheral blood or bone marrow aspirates are obtained from
patients who sign an informed consent, before the initiation of
adjuvant or front-line treatment as part of their initial evaluation.
In this study, we retrospectively identified a total of 165 patients
who had all undergone adjuvant chemotherapy for stage I–II
breast cancer from March 1999 to January 2004, and for whom
paired blood and bone marrow samples before the initiation of any
systemic treatment were available. In 162 (98.2%) of them, a blood
sample was also available after the completion of treatment,
whereas only 84 (50.9%) consented for a repeated bone marrow
aspiration after adjuvant chemotherapy.
Every enrolled patient underwent a complete baseline diagnostic
evaluation to exclude distant metastases before primary surgery,
which consisted of chest X-rays, mammography, abdominal
ultrasound and whole-body bone scan. Further imaging studies
(computed tomography scans and magnetic resonance imaging)
were carried out, if clinically indicated. Surgical treatment was either
mastectomy or lumpectomy with axillary lymph node dissection.
Radiation treatment was given to patients who underwent lumpec-
tomy and to those with four or more axillary lymph nodes. All
patients included in this study underwent adjuvant chemotherapy
and most were treated in the context of research protocols of the
Hellenic Oncology Research Group (HORG). Adjuvant chemother-
apy consisted of either FEC (Fluoruracil, Epirubicin, Cyclopho-
sphamide) or EC/T (Epirubicin, Cyclophosphamide/Taxotere),
or classical CMF (Cyclophosphamide, Methotrexate, Fluoruracil)
(details of the used chemotherapy regimens have been previously
reported; Ignatiadis et al, 2007). Patients with HER2-positive
tumours were not given adjuvant trastuzumab, because all were
treated before the positive results from the adjuvant trastuzumab
trials were reported. Patients with oestrogen receptor (ER)-positive
and/or progesterone receptor (PR)-positive tumours were given
20mg tamoxifen daily for 5 years; pre-menopausal women were also
given luteinising hormone-releasing hormone analogues for 2 years.
Follow-up was conducted every 3 months during the first 2 years,
every 6 months until 5 years after surgery and yearly thereafter, and
it consisted of a clinical examination with routine laboratory studies
(including tumour markers) and imaging studies with X-rays and
abdominal ultrasound (computed tomography scans and magnetic
resonance imaging were carried out, if clinically indicated). The
administration of adjuvant chemotherapy and hormonal treatment
was decided independently of the molecular detection of CTCs or
DTCs. Moreover, during the follow-up period, clinicians were
blinded for the results of CK-19 mRNA detection.
Clinical samples
Peripheral blood (20ml in EDTA) and bone marrow aspirations
(3ml in EDTA aspirated from the posterior iliac crest under local
anaesthesia) were obtained before the initiation of adjuvant
treatment (usually 3 or 4 weeks after primary surgery). Peripheral
blood and bone marrow aspirates were also obtained after the
completion of adjuvant chemotherapy from patients who gave their
consent. All blood samples were obtained from vein puncture after
the first 5ml of blood was discarded; similarly, the initial 0.1–0.2ml
of bone marrow aspirate was discarded. This precaution was
undertaken to avoid a contamination of the blood or bone marrow
samples with epithelial cells from the skin during sample collection.
RNA extraction and real-time PCR assay for CK-19
mRNA-positive cells
For this study, frozen RNA samples stored in the biobank of
the laboratory of Tumour Cell Biology were used. Both peripheral
blood and bone marrow samples had been processed for
mononuclear cell isolation in room temperature within 2–4h
after sampling. Briefly, samples were diluted (vol/vol) with
RNase-free, sterile 0.9% NaCl, and mononuclear cells (peripheral
blood mononuclear cells and bone marrow mononuclear cells,
respectively) were obtained by Ficoll-Hypaque (Sigma-Aldrich, St
Louis, MO, USA) gradient density centrifugation at 1200g for
30min at 41C. Interface cells were obtained, washed twice with
sterile phosphate-buffered saline and stored at  801C until use.
Total RNA isolation was carried out using Trizol LS reagent (Gibco
Life Sciences, BRL, Grand Island, NY, USA), according to the
manufacturer’s instructions. All RNA preparations and handling
steps were conducted in a laminar flow hood, under RNAse-free
conditions. Isolated RNA was dissolved in diethylpyrocarbonate-
treated water and stored at  801C until use. RNA concentration
was determined by absorbance reading at 260nm using the Hitachi
UV–VIS (U-2000) spectrophotometer (Tokyo, Japan). RNA
integrity was tested by PCR amplification of the b-actin house-
keeping gene. RNA isolated from MCF-7 breast cancer and the
ARH-77 leukaemic cell lines was used as positive and negative
controls, respectively.
Reverse transcription of RNA was carried out using the
Thermoscript RT-PCR system (Invitrogen, Paisley, UK). cDNA
was synthesised according to the manufacturer’s instructions. The
real-time RT–PCR assay for the detection of CK-19 mRNA-
positive cells has already been described in detail (Stathopoulou
et al, 2003). In brief, 2ml of cDNA was placed into 18ml of reaction
volume containing 1ml of the sense primer CK-19-for (3mmoll
 1),
1ml of the anti-sense primer CK-19-do (3mmoll
 1), 2.4ml of the
LightCycler-FastStart DNA Master Hybridization probes reagent
(Roche, Mannheim, Germany) (10  concentration), 1ml of the
probe CK-19-FL (3mmoll
 1), and 1ml of the probe CK-19-LC
(3mmoll
 1). The primers used have been described earlier
(Stathopoulou et al, 2003). PCR was initiated with a 10-min
denaturation at 951C and terminated with a 30-s cooling step at
401C. The cycling protocol consisted of a denaturation step at
951C, annealing at 601C for 10s, and extension at 721C, and
repeated 50 times. Fluorescence detection was performed at the
end of each annealing step for o1s. Real-time PCR for the
housekeeping gene GAPDH was performed in all of the clinical
samples to evaluate the quality of the cDNAs used in the study. The
lower detection limit of the assay was set at 0.6 MCF-7 cell
equivalents per 5mg of RNA (Stathopoulou et al, 2003). The
within-run curve values (CVs) for MCF-7 cells as determined by
the calibration curve ranged from 7.5 to 9.3%, whereas the
corresponding crossing point (Cp) values ranged from 0.9 to 1.5%;
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ssimilarly, the between-run CVs ranged from 10.7 to 16.0%,
whereas the corresponding Cp values ranged from 2.2 to 3.2%.
According to the analytic detection limit of our assay, the presence
of X0.6 MCF-7 equivalents per 5mg of total RNA derived from
peripheral blood mononuclear cells was considered as a
positive result (Stathopoulou et al, 2003). Using the above
cutoff values, only 2 out of 89 healthy female donors were positive
(2.2%) (Stathopoulou et al, 2003). Furthermore, none of the nine
women with benign breast disease had positive blood samples.
Twenty-seven bone marrow aspirates from normal donors (n¼7)
or patients with non-epithelial (n¼5) or haematological malig-
nancy (n¼15) served as controls for the determination of the
cutoff point for CK-19 mRNA expression in the bone marrow. The
cutoff value, based on the 95th percentile of the CK-19 mRNA
values of controls, was 0.6 MCF-7 equivalents per 5mg of total
RNA.
Study design
This is a retrospective analysis of prospectively collected data in
the context of an ongoing longitudinal study. The aim of this study
was to evaluate the detection rate and the prognostic relevance of
the presence of CTCs and DTCs in patients with early breast cancer
(McShane et al, 2005). Patients were enrolled during the period
from March 1999 to January 2004. All patients signed an informed
consent, which was approved by the Ethics and Scientific
Committees of our Institution. As of June 2008, median follow-
up time was 59.0 months (range, 13–95). Survival intervals were
calculated from the first dose of chemotherapy until the date of
death or of the first clinical or imaging evidence of disease
recurrence.
Statistical analysis
Differences of rates between groups were compared with either the
two-sided Fisher’s exact test or Pearson’s w
2-test. Differences
between groups in terms of continuous variables were assessed by
the non-parametric Mann–Whitney test. The normality of
continuous variables was verified using the Kolmogorov–Smirnov
test. The Spearman exact test was performed to evaluate the
correlation between the expression of CK-19 mRNA cells in the
peripheral blood and bone marrow (Cox, 1970; Collett, 2003).
Differences in positivity rates between blood and bone marrow
samples were assessed using the McNemar test. The Kaplan–Meier
method was used to estimate DFS and survival curves, and the log-
rank test was used to compare the curves (Altman, 1991; Armitage
and Berry, 1994). The Cox proportional hazards model (Armitage
and Berry, 1994) was used for outcomes related to time-to-event
data and prognostic values. In order to construct such a model
using covariates that have an independent significant influence on
outcomes, a stepwise procedure (unconditional backward) was
carried out (Armitage and Berry, 1994). Before the application of
these methods, univariate analysis was performed for the
preliminary exploration of variables of interest. P-values o0.05
were considered statistically significant for all comparisons.
RESULTS
Patient characteristics
Patient characteristics are listed in Table 1. Patients’ median
age was 54 years (range, 26–75 years), 78 (47.3%) were
pre-menopausal, (111) 91.5% had tumours 42cm, 64 (38.8%)
were of histological grade 3, 64 (38.8%) were ER negative, 33 (20%)
were HER2 positive, and 106 (64.3) had infiltrated axillary lymph
nodes.
Detection of CTCs and DTCs before the initiation of
adjuvant treatment
CK-19 mRNA-positive CTCs and DTCs were detected in 91
(55.2%) and 95 (57.6%) of 165 patients, respectively. No
correlation was found between the detection of CK-19 mRNA-
positive CTCs or DTCs and the patients’ clinical or pathological
characteristics (Table 1). The median number of CTCs and DTCs
was 2.0 (range, 0.6–149) and 2.0 (range, 0.6–732) MCF-7
equivalents per 5mg RNA, respectively (P¼0.743). A strong
correlation was observed between the detection of CK-19 mRNA-
positive cells in peripheral blood and in bone marrow (Spearman
test, Rs¼0.750; P¼0.0001; Figure 1A).
As indicated in Table 2, 88 (53.3%) patients with detectable
DTCs also had detectable CTCs (DTC(þ)/CTC(þ) group); in
addition, in 67 (40.6%) patients, no occult tumour cells could be
detected either in the bone marrow or peripheral blood (DTC( )/
CTC( ) group). In 3 (1.8%) patients with detectable CTCs, no
DTCs were detected (DTC( )/CTC(þ) group), whereas in 7
(4.2%) patients with DTCs, no CTCs were detected (DTC(þ)/
CTC( ) group). Overall, there was 93.9% concordance (in 155 out
of 165 patients) for the presence of occult tumour cells between
peripheral blood and bone marrow, before the initiation of
adjuvant chemotherapy. According to the McNemar test, the
difference in positivity rates between the peripheral blood and
bone marrow CK-19 mRNA expression was not statistically
significant (P¼0.344).
Detection of CTCs and DTCs after the completion of
adjuvant chemotherapy
In 162 patients, repeated blood samples were available after the
completion of adjuvant chemotherapy. The CK-19 mRNA expres-
sion was evident in 79 (48.8%) patients compared with 90 (55.6%)
patients before chemotherapy (P¼0.169). Of 91 patients with
detectable CK-19 mRNA-positive CTCs before chemotherapy, 58
(63.7%) remained positive and 32 (35.2%) were negative for CK-19
mRNA expression after chemotherapy (no data available for 1
patient). The median number of CTCs identified after chemother-
apy was 1.3 (range, 0.6–25.0) equivalents per 5mg of RNA, which
was not significantly different compared with pre-chemotherapy
values (P¼0.341). Conversely, 21 (28.4%) of 74 patients without
detectable CK-19 mRNA-positive CTCs before chemotherapy
became CK-19 mRNA positive after chemotherapy.
In the group of 84 patients with repeated bone marrow samples
available after chemotherapy, 43 (51.2%) had CK-19 mRNA-
positive DTCs compared with 53 (63.1%) patients before
chemotherapy (P¼0.099). In 33 (62.2%) of 53 initially DTC(þ)
patients, occult tumour cells persisted, whereas in 20 (37.7%), no
tumour cells could be identified after chemotherapy. The median
number of DTCs identified after chemotherapy was 1.0 MCF-7 cell
equivalents per 5mg of RNA (range 0.6–87), which was
significantly different compared with pre-chemotherapy values
(P¼0.045). Conversely, among 31 DTC( ) patients before
chemotherapy, 10 (32.2%) had CK-19 mRNA-positive CTCs
identified after chemotherapy.
A strong correlation was observed between the presence of CK-
19 mRNA-positive CTCs and DTCs after chemotherapy (Spearman
test, Rs¼0,696; P¼0.0001, Figure 1B). Indeed, as indicated in
Table 2, 44 (52.4%) out of 84 patients had detectable CTCs in
peripheral blood after chemotherapy. A total of 32 (38.1%) patients
with detectable DTCs also had detectable CTCs and 29 (34.5%)
patients with a CK-19 mRNA-negative bone marrow also presented
with a CK-19 mRNA-negative peripheral blood sample. The
concordance rate for the bone marrow and peripheral blood
CK-19 mRNA expression after the completion of adjuvant chemo-
therapy was 72.6%. According to the McNemar test, the difference
CK-19 mRNAþ CTCs and DTCs in BC
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sin positivity rates between the blood and bone marrow CK-19
mRNA expression was not statistically significant (P¼0.999).
With regard to the concomitant detection of tumour cells in the
peripheral blood and bone marrow in the same group of 84
patients, 9 (18.4%) of the 49 DTC(þ)/CTC(þ) patients before
chemotherapy were found negative in both peripheral blood and
bone marrow, whereas 4 (13.7%) of 29 patients who were
initially DTC( )/CTC( ) became DTC(þ)/CTC(þ). Moreover,
13 (26.5%) of the initially DTC(þ)/CTC(þ) patients, as well as 8
(27.5%) of the initially DTC( )/CTC( ) patients, had detectable
occult tumour cells either in the bone marrow or peripheral blood
after completion of adjuvant chemotherapy.
Clinical relapses and disease-related deaths according to
the detection of CK-19 mRNA-positive CTCs and DTCs
After a median follow-up period of 59.0 months (range, 13–95), 37
(22.4%) patients presented a local and/or distant relapse and 20
(12.1%) died because of disease progression. In the group of
patients with CK-19 mRNA-positive CTCs (CTC(þ) group) before
the initiation of chemotherapy, 25 (27.5%) out of 91 relapsed,
compared with 12 (16.2%) out of 74 patients in the CTC( )g r o u p
(Table 3; P¼0.081). Among the 95 women with CK-19 mRNA-positive
DTCs (DTC(þ)g r o u p ) ,2 6( 2 7 . 4 % )r e l a p s e dc o m p a r e dw i t h1 1
(15.7%) among 70 patients in the DTC( )g r o u p( T a b l e3 ;P¼0.105).
Table 1 Patients’ characteristics
PB BM
CK-19+ CK-19  P-value CK-19+ CK-19  P-value
Patients enrolled (n) 165 91 74 95 70
Age (years)
Median 54 54 54.5 0.647 54 53 0.877
Range 26–75 26–74 36–75 26–74 36–75
n (%) n (%) n (%)
Menopausal status
Pre-menopausal 78 (47.3) 45 (49.5) 33 (44.6) 0.534 44 (46.3) 34 (48.6) 0.774
Post-menopausal 87 (52.7) 46 (50.5) 41 (55.4) 51 (53.7) 36 (51.4)
Tumour size (cm)
o2.0 54 (32.7) 27 (29.7) 27 (36.5) 0.650 29 (30.5) 25 (35.7) 0.768
2.0–5.0 97 (58.8) 56 (61.5) 41 (55.4) 58 (61.1) 39 (55.7)
45.0 14 (8.5) 8 (8.8) 6 (8.1) 8 (8.4) 6 (8.6)
Lymph nodes
0 59 (35.8) 28 (30.8) 31 (41.9) 0.240 30 (31.6) 29 (41.4) 0.294
1–3 59 (35.8) 33 (36.3) 26 (35.1) 34 (35.8) 25 (35.7)
X4 47 (28.5) 30 (33.0) 17 (23.0) 31 (32.6) 16 (22.9)
Histology grade
I/II 79 (47.9) 41 (45.1) 38 (51.4) 0.669 44 (46.3) 35 (50.0) 0.800
III 64 (38.8) 38 (41.8) 26 (35.1) 37 (38.9) 27 (38.6)
Lobular
a 22 (13.3) 12 (13.2) 10 (13.5) 14 (14.7) 8 (11.4)
ER status
ER
+ 101 (61.2) 59 (64.8) 42 (56.8) 0.290 60 (63.2) 41 (58.6) 0.550
ER
  64 (38.8) 32 (35.2) 32 (43.2) 35 (36.8) 29 (41.4)
PR status
PR
+ 88 (53.3) 50 (54.9) 38 (51.4) 0.645 50 (52.6) 38 (54.3) 0.833
PR
  77 (46.7) 41 (45.1) 36 (48.6) 45 (47.4) 32 (45.7)
HER2 status (ICH)
Negative (0–2) 131 (79.4) 78 (85.7) 58 (78.4) 0.290 82 (86.3) 54 (77.1) 0.176
Positive (3+) 33 (20.0) 13 (14.3) 15 (20.3) 13 (13.7) 15 (21.4)
UN 1 (0.6) 1 (1.3) 1 (1.4)
Surgery
S 119 (72.1) 62 (68.1) 57 (77.0) 0.205 64 (67.4) 55 (78.6) 0.113
T 46 (27.9) 29 (31.9) 17 (23.0) 31 (32.6) 15 (21.4)
Adjuvant chemotherapy
FEC 60 (36.4) 37 (40.7) 23 (31.1) 0.055 37 (38.9) 23 (32.9) 0.055
T/EC 98 (59.4) 53 (58.2) 45 (60.8) 57 (60.0) 41 (58.6)
CMF 7 (4.2) 1 (1.1) 6 (8.1) 1 (1.1) 6 (8.6)
RT
Yes 144 (87.3) 83 (91.2) 61 (82.4) 0.093 85 (89.5) 59 (84.3) 0.323
No 21 (12.7) 8 (8.8) 13 (17.6) 10 (10.5) 11 (15.7)
BM¼bone marrow; CK-19¼cytokeratin-19; ER¼oestrogen receptor; PR¼progesterone receptor; PB¼peripheral blood; RT¼radiotherapy; S¼segmentectomy/
lumpectomy; T¼total radical mastectomy; UN¼unknown.
aLobular carcinomas (n¼22) are not scored by histological grade.
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chemotherapy, 15 (16.5%) out of 91 CTC(þ) patients died
compared with 5 (6.8%) out of 74 CTC( ) patients (Table 3). The
Kaplan–Meier survival analysis showed a significantly reduced
probability for OS for patients in the CTC(þ) group compared with
that in the CTC( ) group (log-rank test, P¼0.024; Figure 2A).
Similar results were observed for OS according to DTC status before
chemotherapy. Specifically, 17 (17.9%) out of 95 patients in the
DTC(þ) group died compared with 3 (4.3%) out of 70 patients in
the DTC( )g r o u p( l o g - r a n kt e s t ,P¼0.015; Figure 2B).
In the group of 162 patients with peripheral blood samples
available after the completion of therapy, 22 (27.8%) out of 79 and
15 (18.1%) out of 83 relapsed in CTC(þ) and CTC( ) groups,
respectively (Table 3; P¼0.057). Among the group of 84 patients
with a bone marrow sample obtained after chemotherapy, the
number of relapses was 11 (25.6%) out of 43 and 6 (14.6%) out of
41 patients (P¼0.162) in the DTC(þ) and DTC( ) groups,
respectively. No significant difference was observed in patients’
survival according to the detection of CTCs (P¼0.128) or DTCs
(P¼0.302) after chemotherapy (Table 3).
Clinical outcome according to the concomitant detection of
CK-19 mRNA-positive CTCs and DTCs
The outcome of patients according to the concomitant detection of
CK-19 mRNA-positive CTCs and DTCs before the initiation of
chemotherapy is presented in Table 4. The incidence of relapses
was 27.3 and 14.9% in patients of DTC(þ)/CTC(þ) and DTC( )/
CTC( ) groups before chemotherapy, respectively (Table 4;
P¼0.066); 3 (30%) additional relapses occurred among 10 patients
who had detectable DTCs or CTCs (group ‘other combinations’;
Table 4). A total of 15 (17%) deaths occurred in patients of the
DTC(þ)/CTC(þ) group compared with 3 (4.5%) in the subgroup
of patients with a DTC( )/CTC( ) status before chemotherapy.
The Kaplan–Meier survival analysis showed a significantly longer
OS in patients of the DTC( )/CTC( ) group compared with those
of the DTC(þ)/CTC(þ) group (log-rank test, P¼0.016;
Figure 3A). Moreover, OS was significantly longer in patients with
a DTC( )/CTC( ) status compared with those with at least one
positive result designated as ‘other combinations’ (log-rank test,
P¼0.021; Figure 3B). A total of 6 (22.1%) deaths occurred in the
group of patients who had persistently positive peripheral blood
and bone marrow, both before and after chemotherapy; con-
versely, no deaths were observed in patients without detectable
CK-19 mRNA-positive CTCs and DTCs, either before or after the
completion of chemotherapy (log-rank test, P¼0.036).
Univariate and multivariate analysis
As shown in Table 5, tumour size, histological grade and
X4 involved axillary lymph nodes were significantly associated
with decreased DFS in univariate analysis. Factors associated
with decreased OS were the detection of CTCs, DTCs, as well as the
simultaneous detection of CTCs and DTCs before chemotherapy.
A multivariate analysis including factors that were most
significantly associated with DFS and OS in the univariate analysis
showed that tumour size (P¼0.031) and the involvement of X4
axillary lymph nodes (P¼0.036) were independent factors
associated with decreased DFS (Table 6), whereas histological
grade (P¼0.022), PR negativity (P¼0.013), and the detection of
DTCs before chemotherapy (P¼0.032) were independently
associated with decreased OS (Table 6). Owing to the significant
correlation observed between the detection of CTCs and DTCs,
the CTC status before chemotherapy was not included in the
multivariate analysis.
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Figure 1 Correlation between the presence of CTCs and DTCs before
initiation (A) and after the completion (B) of adjuvant chemotherapy.
Table 2 Concordance of CTCs and DTCs
Pre-chemotherapy (n¼165) Post-chemotherapy (n¼84)
n
CTC(+)
91 (55.2%)
CTC( )
74 (44.8%) n
CTC(+)
44 (52.4%)
CTC( )
40 (47.6%)
DTC(+)
95 (57.6%)
88 (53.3%) 7 (4.2%) DTC (+)
43 (51.2%)
32 (38.1%) 11 (13.1%)
DTC( )
70 (42.4%)
3 (1.8%) 67 (40.6%) DTC ( )
41 (48.8%)
12 (14.2%) 29 (34.5%)
CTC¼circulating tumour cell; DTC¼disseminated tumour cell.
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sDISCUSSION
The data presented in this study show that there is a significant
concordance between the detection of CK-19 mRNA-positive cells
detected in the peripheral blood (CTCs) and in bone marrow
(DTCs) of patients with early breast cancer, both before initiation
and after completion of adjuvant chemotherapy. In addition, it was
shown that the detection of CTCs or DTCs before chemotherapy
was associated with decreased survival of patients.
Using a quantitative RT-PCR for detecting CK-19 mRNA-
positive cells, we observed a concordance rate of 93.9 and 72.6%
between peripheral blood and bone marrow samples obtained
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Figure 3 Overall survival curves of patients with early breast cancer
according to the concomitant detection of CTCs and DTCs. (A) Both
positive vs both negative. (B) Both negative vs at least one positive (‘other
combinations’).
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Figure 2 Overall survival curves of patients with early breast cancer
according to the detection of CTCs (A) and DTCs (B) before
chemotherapy.
Table 3 Incidence of relapses and disease-related deaths according to the detection of CK-19 mRNA(+) CTCs and DTCs as considered separately
Relapse
n (%) P-value
Death
n (%) P-value
Pre-chemotherapy
CTC status (n¼165) CTC(+) (n¼91) 25 (27.5%) 15 (16.5%)
CTC( )( n¼74) 12 (16.2) 0.081 5 (6.8) 0.024
DTC status (n¼165) DTC(+) (n¼95) 26 (27.4) 17 (17.9)
DTC( )( n¼70) 11 (15.7) 0.105 3 (4.3) 0.015
Post-chemotherapy
CTC status (n¼162) CTC(+) (n¼79) 22 (27.8) 12 (15.2)
CTC( )( n¼83) 15 (18.1) 0.057 8 (9.6) 0.128
DTC status (n¼84) DTC(+) (n¼43) 11 (25.6) 7 (16.3)
DTC( )( n¼41) 6 (14.6) 0.162 5 (12.2) 0.302
CK-19¼cytokeratin-19; CTC¼circulating tumour cell; DTC¼disseminated tumour cell. Significant P-values are shown in bold.
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respectively, in patients with early breast cancer. Similar observa-
tions have been reported by other investigators who evaluated the
presence of CK-positive cells in the peripheral blood and bone
marrow using immunocytochemical assays (Witzig et al, 2002;
Pierga et al, 2004; Muller et al, 2005; Wiedswang et al, 2006). In a
previous report from our group, we reported a weaker correlation
between the detection of CK-19 mRNA expression in blood and in
the bone marrow in a smaller series of patients with early breast
cancer using a qualitative nested RT-PCR assay (Stathopoulou
et al, 2002). Differences in the assays used could account for these
discrepancies. Indeed, Schoenfeld et al (1997) have reported that
the concordance between blood and bone marrow samples for
occult tumour cell detection was only 6% by immunocytochem-
istry and 27% by RT-PCR.
The lack of a complete overlap between the presence of CK-19
mRNA-positive CTCs and DTCs either before (Ismail et al, 2004;
Pierga et al, 2004; Muller et al, 2005; Wiedswang et al, 2006) or after
chemotherapy (Slade et al, 2009) could be related to the fact that
occult tumour cells are rare events and therefore their evaluation is
greatly influenced by sampling variability. In addition, it has been
suggested that blood represents a temporary compartment for
Table 5 Predictive and prognostic factors by univariate analyses (unadjusted relative risk) for DFS and OS
Log-rank test P-value Hazard ratio P-value 95% CI
DFS
CTC (+ vs  )
apre- (n¼165) 3.042 0.081 1.827 0.087 0.917–3.641
DTC (+ vs  ) pre- (n¼165) 2.621 0.105 1.775 0.111 0.876–3.597
CTC (+ vs  )
apost- (n¼162) 3.613 0.057 1.873 0.062 0.969–3.621
DTC (+ vs  ) post- (n¼84) 1.960 0.162 2.008 0.171 0.741–5.441
DTC+/CTC+ vs DTC /CTC  pre- (n¼155) 3.189 0.074 1.933 0.080 0.924–4.046
DTC/CTC at least one (+) vs both ( ) pre-(n¼165) 3.170 0.075 1.910 0.081 0.924–3.949
DTC/CTC at least one (+) vs both ( ) post-(n¼84) 1.891 0.169 2.162 0.180 0.701–6.668
Menopausal status (post vs pre) (n¼165) 3.300 0.069 1.851 0.074 0.941–3.641
Tumour size (42 vs p2cm)(n¼165) 6.495 0.011 2.655 0.015 1.213–5.809
Grade (III vs I/II) (n¼143) 6.969 0.008 2.435 0.011 1.229–4.824
Nodal involvement (X4 vs 0–3) (n¼165) 6.525 0.011 2.275 0.013 1.188–4.357
ER (  vs +) (n¼165) 1.182 0.277 1.428 0.281 0.747–2.727
PR (  vs +) (n¼165) 3.349 0.067 1.829 0.072 0.947–3.531
Adjuvant CMT (Other vs T/EC) (n¼165) 2.260 0.133 1.636 0.138 0.854–3.134
OS
CTC (+ vs  ) pre- (n¼165) 5.125 0.024 3.319 0.033 1.101–10.004
DTC (+ vs  ) pre- (n¼165) 5.866 0.015 4.074 0.026 1.187–13.990
CTC (+ vs  ) post- (n¼162) 2.311 0.128 2.034 0.137 0.798–5.183
DTC (+ vs  ) post- (n¼84) 1.063 0.302 1.889 0.311 0.552–6.463
DTC+/CTC+ vs DTC /CTC  pre-(n¼155) 5.857 0.016 4.094 0.026 1.185–14.144
DTC/CTC at least one (+) vs both ( ) pre-(n¼165) 5.309 0.021 3.839 0.033 1.118–13.180
DTC/CTC at least one (+) vs both ( ) post-(n¼84) 2.173 0.140 3.002 0.161 0.647–13.943
Menopausal status (post- vs pre-) (n¼165) 1.210 0.271 1.678 0.277 0.660–4.269
Tumour size (42 vs p2cm)(n¼165) 4.884 0.027 3.657 0.039 1.065–12.552
Grade (III vs I/II) (n¼143) 7.587 0.006 3.653 0.010 1.366–9.770
Nodal involvement (X4 vs 0–3) (n¼165) 3.743 0.053 2.379 0.061 0.961–5.890
ER (  vs +) (n¼165) 5.115 0.024 2.798 0.031 1.101–7.110
PR (  vs +) (n¼165) 8.712 0.003 4.549 0.007 1.507–13.734
Adjuvant CMT (T/EC vs other) (n¼165) 0.210 0.729 1.174 0.729 0.474–2.903
 ¼negative; +¼positive; CI¼confidence interval; CTC¼circulating tumour cell; DFS¼disease-free survival; DTC¼disseminated tumour cell; ER¼oestrogen receptor;
OS¼overall survival; PR¼progesterone receptor.
apre- and post- refer to the pre- and post-chemotherapy values CTC and DTC. Significant P-values are shown in bold.
Table 6 Multivariate analysis for DFS and OS
Parameter Hazard ratio 95% CI P-value
DFS
Tumour size (42 vs p2cm) 2.391 1.085–5.273 0.031
Lymph nodes (X4 vs 0–3) 2.014 1.045–3.881 0.036
OS
Histology grade (III vs I/II) 3.220 1.184–8.762 0.022
PR (  vs +) 4.061 1.337–12.332 0.013
DTC (+ vs  ) pre-chemotherapy 3.859 0.119–13.303 0.032
CI¼confidence interval; DFS¼disease-free survival; DTC¼disseminated tumour
cell; OS¼overall survival; PR¼progesterone receptor. Significant P-values are shown
in bold.
Table 4 Incidence of relapses and disease-related deaths according to the concomitant detection of CK-19 mRNA(+) CTCs and DTCs pre-
chemotherapy
Clinical relapses Deaths
DTC/CTC status Yes No P-value Yes No P-value
CTC(+)/DTC(+) (n¼88) 24 (27.3%) 64 (72.7%) 15 (17.0%) 73 (83.0%)
CTC( )/DTC( )( n¼67) 10 (14.9%) 57 (85.1%) 0.066 3 (4.5%) 64 (95.5%) 0.016
Other combinations
a (n¼10) 3 (30.0%) 7 (70.0%) 2 (20.0%) 16 (80.0%)
CK-19¼cytokeratin-19; CTC¼circulating tumour cell; DTC¼disseminated tumour cell.
a(CTC(+)/DTC( ) or CTC( )/DTC(+)). Significant P-values are shown in bold.
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tion of CTCs can settle in distant organs such as the bone marrow
(Muller et al, 2005). Nevertheless, the high concordance observed
between CTC and DTC detection in our study favours the
hypothesis that there is a continuous circulation and exchange of
epithelial cells between bone marrow and peripheral blood.
The high detection rate of occult tumour cells in both peripheral
blood and bone marrow observed in the current study is in overt
contrast with previous studies reporting low detection rates using
immunocytochemical assays (Ismail et al,2 0 0 4 ;P i e r g aet al,2 0 0 4 ;
Muller et al, 2005; Wiedswang et al, 2006; Benoy et al, 2006) and
should be attributed to the high sensitivity and specificity of the
quantitative RT-PCR assay used for the detection of minimal residual
disease (Stathopoulou et al, 2003). Moreover, it is interesting to note
that only 10% of 1767 patients with early disease had more than one
CTC per 23ml of peripheral blood when tested with the new
automated Cell Search System (Rack et al, 2007, 2008).
This analysis also shows that CK-19 mRNA-positive tumour
cells persist in the blood and/or bone marrow of patients with early
breast cancer despite the administration of adjuvant chemother-
apy. Indeed, 63.7 and 62.2% of patients in the CTC(þ) and
DTC(þ) groups before the initiation of chemotherapy, respec-
tively, had occult tumour cells detected in their blood or bone
marrow after chemotherapy. In addition, 28.4 and 32.2% of
patients without detectable CTCs or DTCs, before chemotherapy,
respectively, presented with CK-19 mRNA-positive cells after the
completion of adjuvant chemotherapy. This observation suggests
that chemoresistant cells in patients identified as DTC( ) or/and
CTC( ) because of a low tumour load that is undetectable by the
assay could proliferate during the administration of adjuvant
chemotherapy and reach the detection limit after the end of
treatment. Moreover, the increase in discordance between the
detection of CTCs and DTCs after chemotherapy suggests that
CTCs and DTCs represent biologically and genetically different
cells with a variable sensitivity to chemotherapy.
The above observations point to the presence of subpopulations
of CTCs or/and DTCs that bear an inherent resistance to the
chemotherapy regimen used as adjuvant treatment. The presence
of chemoresistant CTCs or DTCs has been previously described
(Braun et al, 2000a; Xenidis et al, 2003, 2009) and attributed to the
low proliferative capacity of these cells (Pantel et al, 1993; Muller
et al, 2005). Therefore, it could be hypothesised that the detection
of occult tumour cells after the completion of adjuvant
chemotherapy could be used as a surrogate marker for the efficacy
of the adjuvant treatment used.
Previous reports evaluating the prognostic significance of
disseminated tumour cells in blood and bone marrow concluded
that the detection of CTCs is prognostically inferior to the
detection of DTCs (Pierga et al, 2004; Benoy et al, 2006;
Wiedswang et al, 2006). In this study, the presence of CK-19
mRNA-positive CTCs and DTCs before the initiation of adjuvant
chemotherapy was predictive for decreased OS. Moreover, in the
multivariate analysis, the detection of DTCs was an independent
prognostic factor associated with a significantly higher risk of
death.
Several reports have shown that the persistence of occult tumour
cells in the bone marrow (Wiedswang et al, 2004; Janni et al, 2005)
or peripheral blood (Xenidis et al, 2003, 2007, 2009) after adjuvant
chemotherapy or during follow-up is associated with an adverse
clinical outcome. In this study, the detection of CTCs and/or DTCs
after chemotherapy was not associated with increased risk for
relapse or death. Further prospective studies including a larger
number of patients are needed to clarify which is the most relevant
time point for the evaluation of minimal residual disease before or
after adjuvant chemotherapy. Moreover, the reproducibility and
stability of the assays used should also be evaluated in a routine
clinical setting.
In conclusion, the results of this study indicate that the detection
of CK-19 mRNA-positive DTCs and CTCs both before and after
chemotherapy is correlated in patients with early-stage breast
cancer. The determination of the CTC status was shown to convey
prognostic information that was of comparable clinical relevance
with that of DTC status. However, for convenience, the detection of
CTCs could be used as an alternative to bone marrow for the
identification of occult breast cancer cells and for monitoring
minimal residual disease. This is of particular interest in the light
of the results of recent trials, indicating that sequential treatment
during the disease-free period may improve OS in breast cancer
(Coombes et al, 2007; Kaufmann et al, 2007). Conceivably,
secondary adjuvant treatment could be administered in patients
selected on the basis of persisting CTCs. However, this should be
tested in prospective clinical trials.
ACKNOWLEDGEMENTS
This work was partly supported by research grants from Pfizer
Pharmaceuticals and the Cretan Association for Biomedical
Research (CABR).
REFERENCES
Altman GD (1991) Practical Statistics for Medical Research. Chapman and
Hall: London, UK
Armitage P, Berry G (1994) Statistical Methods in Medical Research (3rd
edn). Blackwell Scientific: Oxford, UK
Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpe S, Van Marck E,
Vermeulen PB, Dirix LY (2006) Real-time RT-PCR detection of
disseminated tumour cells in bone marrow has superior prognostic
significance in comparison with circulating tumour cells in patients with
breast cancer. Br J Cancer 94: 672–680
Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer
H, Pantel K (2000a) Lack of effect of adjuvant chemotherapy on the
elimination of single dormant tumor cells in bone marrow of high-risk
breast cancer patients. J Clin Oncol 18: 80–86
Braun S, Naume B (2005) Circulating and disseminated tumor cells. J Clin
Oncol 23: 1623–1626
B r a u nS ,P a n t e lK ,M u l l e rP ,J a n n iW ,H e p pF ,K e n t e n i c hC R ,G a s t r o p hS ,
Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G (2000b)
Cytokeratin-positive cells in the bone marrow and survival of patients with
stage I, II, or III breast cancer. NE n g lJM e d342: 525–533
Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE,
Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I,
Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E,
Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE,
Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A,
Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M,
Colajori E, Subar M, Ireland E, Bliss JM (2007) Survival and safety of
exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment
(Intergroup Exemestane Study): a randomised controlled trial. Lancet
369: 559–570
Collett D (2003) Modelling Binary Data. Chapman and Hall/CRC:
London, UK
Cox DR (1970) The Analysis of Binary Data. Methuen: London, UK
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben
JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating
tumor cells, disease progression, and survival in metastatic breast cancer.
N Engl J Med 351: 781–791
Dowlatshahi K, Fan M, Snider HC, Habib FA (1997) Lymph node
micrometastases from breast carcinoma: reviewing the dilemma. Cancer
80: 1188–1197
EBCTC Group (1998) Polychemotherapy for early breast cancer: an
overview of the randomised trials. Early Breast Cancer Trialists’
Collaborative Group. Lancet 352: 930–942
CK-19 mRNAþ CTCs and DTCs in BC
A Daskalaki et al
596
British Journal of Cancer (2009) 101(4), 589–597 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sEBCTC Group (2005) Effects of chemotherapy and hormonal therapy for
early breast cancer on recurrence and 15-year survival: an overview of
the randomised trials. Lancet 365: 1687–1717
Giatromanolaki A, Koukourakis MI, Kakolyris S, Mavroudis D, Kouroussis
C, Mavroudi C, Perraki M, Sivridis E, Georgoulias V (2004) Assessment
of highly angiogenic and disseminated in the peripheral blood disease in
breast cancer patients predicts for resistance to adjuvant chemotherapy
and early relapse. Int J Cancer 108: 620–627
Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M,
Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou
C, Georgoulias V, Mavroudis D (2007) Different prognostic value of
cytokeratin-19 mRNA positive circulating tumor cells according to
estrogen receptor and HER2 status in early-stage breast cancer. J Clin
Oncol 25: 5194–5202
Ismail MS, Wynendaele W, Aerts JL, Paridaens R, Gaafar R, Shakankiry N,
Khaled HM, Christiaens MR, Wildiers H, Omar S, Vandekerckhove P,
Van Oosterom AT (2004) Detection of micrometastatic disease and
monitoring of perioperative tumor cell dissemination in primary
operable breast cancer patients using real-time quantitative reverse
transcription-PCR. Clin Cancer Res 10: 196–201
Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H,
Pantel K, Gerber B, Friese K (2005) The persistence of isolated tumor
cells in bone marrow from patients with breast carcinoma predicts an
increased risk for recurrence. Cancer 103: 884–891
Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, von
Minckwitz G (2007) Improved overall survival in postmenopausal
women with early breast cancer after anastrozole initiated after treatment
with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
J Clin Oncol 25: 2664–2670
Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC (1999)
Outcome of primary-breast-cancer patients with micrometastases: a
long-term follow-up study. Lancet 354: 197–202
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM
(2005) Reporting recommendations for tumor marker prognostic studies
(REMARK). J Natl Cancer Inst 97: 1180–1184
Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F,
Pantel K (2005) Circulating tumor cells in breast cancer: correlation to
bone marrow micrometastases, heterogeneous response to systemic
therapy and low proliferative activity. Clin Cancer Res 11: 3678–3685
Pantel K, Cote RJ, Fodstad O (1999) Detection and clinical importance of
micrometastatic disease. J Natl Cancer Inst 91: 1113–1124
Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I,
Izbicki JR, Riethmuller G (1993) Differential expression of proliferation-
associated molecules in individual micrometastatic carcinoma cells.
J Natl Cancer Inst 85: 1419–1424
Pierga JY, Bonneton C, Vincent-Salomon A, de Cremoux P, Nos C, Blin N,
Pouillart P, Thiery JP, Magdelenat H (2004) Clinical significance of
immunocytochemical detection of tumor cells using digital microscopy
in peripheral blood and bone marrow of breast cancer patients. Clin
Cancer Res 10: 1392–1400
Rack BK, Schindlbeck C, Hofmann S, Schneeweiss A., Rezai M, Beckmann
M, Pantel K, Schneider A, Sommer H, Janni W (2007) Circulating tumor
cells (CTCs) in peripheral blood of primary breast cancer patients. J Clin
Oncol 25: 18S; (abstract no. 10595)
Rack BK, Schindlbeck C, Hofmann S, Schneeweiss A, Hilfrich J, Lorenz R,
Beckmann MW, Pantel K, Lichtenegger W, Sommer HL, Janni WJ (2008)
Prognostic relevance of circulating tumor cells (CTCs) in peripheral
blood of breast cancer patients before and after adjuvant chemotherapy:
The German SUCCESS-Trial. J Clin Oncol 26: 20S; (abstract no. 503)
Schoenfeld A, Kruger KH, Gomm J, Sinnett HD, Gazet JC, Sacks N, Bender
HG, Luqmani Y, Coombes RC (1997) The detection of micrometastases
in the peripheral blood and bone marrow of patients with breast cancer
using immunohistochemistry and reverse transcriptase polymerase
chain reaction for keratin 19. Eur J Cancer 33: 854–861
Slade MJ, Payne R, Riethdorf S, Ward B, Zaidi SA, Stebbing J, Palmieri C,
Sinnett HD, Kulinskaya E, Pitfield T, McCormack RT, Pantel K, Coombes
RC (2009) Comparison of bone marrow, disseminated tumour cells and
blood-circulating tumour cells in breast cancer patients after primary
treatment. Br J Cancer 100: 160–166
Slade MJ, Smith BM, Sinnett HD, Cross NC, Coombes RC (1999)
Quantitative polymerase chain reaction for the detection of micro-
metastases in patients with breast cancer. J Clin Oncol 17: 870–879
Stathopoulos EN, Sanidas E, Kafousi M, Mavroudis D, Askoxylakis J,
Bozionelou V, Perraki M, Tsiftsis D, Georgoulias V (2005) Detection of
CK-19 mRNA-positive cells in the peripheral blood of breast cancer
patients with histologically and immunohistochemically negative axillary
lymph nodes. Ann Oncol 16: 240–246
Stathopoulou A, Gizi A, Perraki M, Apostolaki S, Malamos N, Mavroudis D,
Georgoulias V, Lianidou ES (2003) Real-time quantification of CK-19
mRNA-positive cells in peripheral blood of breast cancer patients using
the LightCycler system. Clin Cancer Res 9: 5145–5151
Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C,
Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N,
Reppa D, Georgoulias V (2002) Molecular detection of cytokeratin-19-
positive cells in the peripheral blood of patients with operable breast
cancer: evaluation of their prognostic significance. J Clin Oncol 20:
3404–3412
Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland JM, Qvist H,
Schlichting E, Sauer T, Janbu J, Harbitz T, Naume B (2003) Detection of
isolated tumor cells in bone marrow is an independent prognostic factor
in breast cancer. J Clin Oncol 21: 3469–3478
Wiedswang G, Borgen E, Karesen R, Qvist H, Janbu J, Kvalheim G, Nesland
JM, Naume B (2004) Isolated tumor cells in bone marrow three years
after diagnosis in disease-free breast cancer patients predict unfavorable
clinical outcome. Clin Cancer Res 10: 5342–5348
Wiedswang G, Borgen E, Schirmer C, Karesen R, Kvalheim G, Nesland JM,
Naume B (2006) Comparison of the clinical significance of occult
tumor cells in blood and bone marrow in breast cancer. Int J Cancer 118:
2013–2019
Witzig TE, Bossy B, Kimlinger T, Roche PC, Ingle JN, Grant C, Donohue J,
Suman VJ, Harrington D, Torre-Bueno J, Bauer KD (2002) Detection of
circulating cytokeratin-positive cells in the blood of breast cancer
patients using immunomagnetic enrichment and digital microscopy. Clin
Cancer Res 8: 1085–1091
Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S,
Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulias
V, Mavroudis D (2009) Cytokeratin-19 mRNA-positive circulating tumor
cells after adjuvant chemotherapy in patients with early breast cancer.
J Clin Oncol 27: 2177–2184
Xenidis N, Markos V, Apostolaki S, Perraki M, Pallis A, Sfakiotaki G,
Papadatos-Pastos D, Kalmanti L, Kafousi M, Stathopoulos E,
Kakolyris S, Mavroudis D, Georgoulias V (2007) Clinical relevance of
circulating CK-19 mRNA-positive cells detected during the adjuvant
tamoxifen treatment in patients with early breast cancer. Ann Oncol 18:
1623–1631
Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A,
Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C,
Argyraki K, Lianidou ES, Stathopoulos S, Georgoulias V, Mavroudis D
(2006) Predictive and prognostic value of peripheral blood cyto-
keratin-19 mRNA-positive cells detected by real-time polymerase
chain reaction in node-negative breast cancer patients. J Clin Oncol 24:
3756–3762
Xenidis N, Vlachonikolis I, Mavroudis D, Perraki M, Stathopoulou A,
Malamos N, Kouroussis C, Kakolyris S, Apostolaki S, Vardakis N,
Lianidou E, Georgoulias V (2003) Peripheral blood circulating
cytokeratin-19 mRNA-positive cells after the completion of adjuvant
chemotherapy in patients with operable breast cancer. Ann Oncol 14:
849–855
CK-19 mRNAþ CTCs and DTCs in BC
A Daskalaki et al
597
British Journal of Cancer (2009) 101(4), 589–597 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s